Total Payments
$10,808
2024 Payments
$214.38
Companies
28
Transactions
515
Medicare Patients
2,515
Medicare Billing
$385,748
Payment Breakdown by Category
Food & Beverage$10,808 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,808 | 515 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $1,516 | 58 | $0 (2024) |
| Lundbeck LLC | $1,426 | 77 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $1,325 | 72 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $1,016 | 39 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $958.82 | 48 | $0 (2022) |
| Alkermes, Inc. | $856.89 | 44 | $0 (2023) |
| ABBVIE INC. | $787.99 | 44 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $496.35 | 17 | $0 (2024) |
| Allergan, Inc. | $425.48 | 25 | $0 (2020) |
| Indivior Inc. | $371.23 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $214.38 | 9 | Neurocrine Biosciences, Inc. ($99.64) |
| 2023 | $885.40 | 44 | AbbVie Inc. ($133.66) |
| 2022 | $2,411 | 114 | Sunovion Pharmaceuticals Inc. ($476.32) |
| 2021 | $1,861 | 89 | Janssen Pharmaceuticals, Inc ($443.89) |
| 2020 | $857.32 | 44 | Takeda Pharmaceuticals U.S.A., Inc. ($196.61) |
| 2019 | $2,057 | 93 | Janssen Pharmaceuticals, Inc ($418.25) |
| 2018 | $1,024 | 47 | Otsuka America Pharmaceutical, Inc. ($258.05) |
| 2017 | $1,497 | 75 | Lundbeck LLC ($424.50) |
All Payment Transactions
515 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Neuropsychiatry | ||||||
| 07/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: Neuropsychiatry | ||||||
| 07/24/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Neurology | ||||||
| 06/18/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $44.11 | General |
| Category: BH | ||||||
| 05/29/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Neuroscience | ||||||
| 05/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Neuropsychiatry | ||||||
| 03/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Neuropsychiatry | ||||||
| 03/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: Neuropsychiatry | ||||||
| 02/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: NEUROSCIENCE | ||||||
| 12/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: BH | ||||||
| 07/11/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: PSYCHIATRY | ||||||
| 05/25/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Neuroscience | ||||||
| 05/10/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.91 | General |
| Category: Neuropsychiatry | ||||||
| 05/04/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 05/04/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.05 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 04/26/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: CNS | ||||||
| 04/25/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Central Nervous System | ||||||
| 04/25/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Central Nervous System | ||||||
| 04/06/2023 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Food and Beverage | Cash or cash equivalent | $20.29 | General |
| Category: PSYCHIATRY | ||||||
| 04/04/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 590 | 838 | $263,538 | $74,629 |
| 2022 | 8 | 673 | 1,307 | $422,210 | $115,777 |
| 2021 | 6 | 587 | 1,195 | $295,560 | $108,011 |
| 2020 | 7 | 665 | 1,038 | $214,175 | $87,331 |
Total Patients
2,515
Total Services
4,378
Medicare Billing
$385,748
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 197 | 204 | $76,579 | $22,049 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 138 | 215 | $88,150 | $20,525 | 23.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 109 | $31,950 | $10,795 | 33.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 58 | 130 | $25,403 | $8,618 | 33.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 106 | 140 | $21,085 | $7,494 | 35.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 27 | 27 | $16,335 | $3,891 | 23.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 13 | 13 | $4,036 | $1,256 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 148 | 478 | $184,275 | $44,738 | 24.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 224 | 242 | $92,340 | $27,133 | 29.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 86 | 213 | $64,590 | $18,340 | 28.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 96 | 181 | $27,170 | $9,178 | 33.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 66 | 137 | $28,285 | $8,235 | 29.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 20 | 20 | $11,180 | $3,389 | 30.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $9,365 | $3,335 | 35.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 13 | 16 | $5,005 | $1,429 | 28.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 144 | 438 | $133,590 | $41,282 | 30.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 276 | 298 | $80,460 | $34,172 | 42.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 90 | 365 | $54,750 | $22,406 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 54 | $14,310 | $4,771 | 33.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 25 | 25 | $9,375 | $4,003 | 42.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 14 | 15 | $3,075 | $1,377 | 44.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 269 | 289 | $67,880 | $34,208 | 50.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 122 | 288 | $71,850 | $23,519 | 32.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 111 | 264 | $36,550 | $16,315 | 44.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 80 | 106 | $18,900 | $5,762 | 30.5% |
About Dr. Lukas Alexanian, MD
Dr. Lukas Alexanian, MD is a Psychiatry healthcare provider based in Lakewood Ranch, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780646331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lukas Alexanian, MD has received a total of $10,808 in payments from pharmaceutical and medical device companies, with $214.38 received in 2024. These payments were reported across 515 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($10,808).
As a Medicare-enrolled provider, Alexanian has provided services to 2,515 Medicare beneficiaries, totaling 4,378 services with total Medicare billing of $385,748. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Lakewood Ranch, FL
- Active Since 04/06/2006
- Last Updated 01/02/2026
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1780646331
Products in Payments
- LATUDA (Drug) $1,325
- VRAYLAR (Drug) $1,213
- REXULTI (Drug) $1,072
- ABILIFY MAINTENA (Drug) $1,031
- INVEGA SUSTENNA (Drug) $946.51
- ARISTADA (Drug) $796.49
- TRINTELLIX (Drug) $770.01
- SPRAVATO (Drug) $542.00
- INGREZZA (Drug) $496.35
- PERSERIS (Drug) $371.23
- AUSTEDO (Drug) $303.09
- NUEDEXTA (Drug) $299.43
- Trintellix (Drug) $253.45
- Fanapt (Drug) $203.14
- CAPLYTA (Drug) $113.97
- VYVANSE (Drug) $101.72
- ABILIFY MYCITE (Drug) $78.73
- Vyvanse (Drug) $68.85
- MYDAYIS (Drug) $68.32
- BRINTELLIX (Drug) $67.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.